Brickell Biotech: Up after excess sweat therapy receives Japan’s approval

** Drug developer’s shares rise 5% to 82 cents premarket

** Co’s Japanese development partner, Kaken Pharmaceutical, receives approval to manufacture and market sofpironium bromide gel (5%) in Japan for treatment of primary axillary hyperhidrosis, which is characterized by excessive sweating in the armpits

** Says Japan is the first country to approve sofpironium bromide, with commercial launch expected later this year

** Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 2020

** As of Thursday’s close, BBI shares fell ~48% YTD (Reporting by Shreyasee Raj in Bengaluru)

Football news:

Gattuso about 1:0 Sociedad: match depended, decide whether Napoli the task of advancing to the playoffs the Europa League more than half
The fall of the Portuguese, whom Cristiano put above himself. From Chelsea and Mercedes in 16-to viewing in Kuban and term for drugs
Juve are in talks with the sacked Sarri to terminate their contract. The coach received 5.5 million euros a year
Fonseca Pro 0:0 with CSKA Sofia: The quality of Roma's game in Serie A is different, but that's normal. Rotation is needed
Wolfsberg midfielder Lindl is among the contenders for the Europa League player of the week. He scored 3 goals for Feyenoord
Arteta after 3:0 with Dundalk: now it will be more difficult for me to choose the starting line-up for Arsenal
Cherchesov congratulated Maradona on his 60th birthday: Human happiness, Diego!